Chugai Pharmaceutical Co., Ltd.
CHGCYOTCHealthcare● Active
$23.50
+$0.44(+1.91%)
Market Cap$77.4B
P/E Ratio—
52W High$34.84
52W Low$19.5
Chugai Pharmaceutical Co., Ltd. (CHGCY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CHGCY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.319T | $1.171T | $1.111T | $1.260T | $1.000T |
| Cost of Revenue | $0.381T | $0.339T | $0.413T | $0.476T | $0.338T |
| Gross Profit | $0.938T | $0.831T | $0.698T | $0.784T | $0.662T |
| Gross Margin %(computed) | 71.09% | 71.01% | 62.81% | 62.20% | 66.18% |
| Operating Expenses | |||||
| R&D Expenses | $0.197T | $0.181T | $0.175T | $0.150T | $0.137T |
| G&A Expenses | $0.000T | $0.000T | $0.000T | $0.024T | $0.026T |
| Total Operating Expenses | $0.319T | $0.289T | $0.259T | $0.250T | $0.240T |
| Operating Income | $0.619T | $0.542T | $0.439T | $0.533T | $0.422T |
| Operating Margin %(computed) | 46.92% | 46.30% | 39.52% | 42.33% | 42.20% |
| Interest Income | $0.004T | $0.000T | $0.005T | $0.000T | $0.000T |
| Interest Expense | $0.001T | ($0.001T) | $0.000T | $0.000T | $0.000T |
| Income Before Tax | $0.627T | $0.543T | $0.444T | $0.531T | $0.419T |
| Income Tax Expense | $0.172T | $0.156T | $0.118T | $0.157T | $0.116T |
| Net Income | $0.455T | $0.387T | $0.325T | $0.374T | $0.303T |
| Net Margin %(computed) | 34.50% | 33.09% | 29.29% | 29.72% | 30.31% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $138.26 | $117.70 | $98.90 | $113.82 | $92.15 |
| Wtd Avg Shares | 0.003T | 0.003T | 0.003T | 0.003T | 0.003T |
| EBITDA | $0.662T | $0.574T | $0.471T | $0.565T | $0.450T |
| EBITDA Margin %(computed) | 50.19% | 49.01% | 42.37% | 44.82% | 45.04% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · JPY · T
Explore more Chugai Pharmaceutical Co., Ltd. data
About Chugai Pharmaceutical Co., Ltd. (CHGCY) Income Statement
Chugai Pharmaceutical Co., Ltd. (CHGCY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CHGCY reported revenue of $1318.93B, gross profit of $937.60B (gross margin 71.09%), and net income of $455.05B — a net profit margin of 34.50%.
Frequently asked questions
CHGCY · 4 questionsChugai Pharmaceutical Co., Ltd. (CHGCY) reported revenue of $1318.93B for 2025, up 12.7% year-over-year.
CHGCY revenueCHGCY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09